Voyager Therapeutics, Inc. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Robin Swartz, current COO of Voyager Therapeutics, was promoted to President effective October 20, 2026, reporting to CEO Alfred Sandrock. New compensation includes base salary of $625,000 (50% bonus target); promotion equity grant of 318,500 options and 68,250 RSUs vesting over 4 and 3 years respectively, both granted November 1, 2026. Upon termination within 12 months post-Sale Event, receives 12 months base salary, pro-rated bonus, 12 months COBRA, and 100% equity acceleration.
Why this rating
Executive promotion is routine; equity grant (~$3.5M at current valuation) is material to Swartz individually but modest relative to $144M market cap (~2.4%). No business change signaled.
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.